Key Highlights
- HC Bioscience appoints Simon Tsang, Ph.D., as Chief Business Officer.
- Dr. Tsang to spearhead business development initiatives for tRNA-based therapies.
- He brings over 20 years of experience in biotech and business development.
- HC Bioscience advances novel treatments for Hemophilia, Duchenne muscular dystrophy, and cancer.
Source: Business Wire
Notable Quotes
- “Simon’s combination of business acumen and scientific knowledge is a tremendous asset to our team. His leadership will be critical as we advance our lead program in Hemophilia towards clinical trials and continue to develop groundbreaking treatments.” — Leslie Williams, CEO and Founder at HC Bioscience
- “The team’s commitment and innovative approach to protein editing have the potential to treat a wide range of genetically defined diseases. I look forward to driving the strategic advancement of this new therapeutic modality.” — Simon Tsang, Ph.D., Chief Business Officer at HC Bioscience
SoHC's Take
HC Bioscience’s appointment of Simon Tsang, Ph.D., as Chief Business Officer is a strategic move that strengthens the company’s leadership as it continues to develop first-in-class tRNA-based therapies. Dr. Tsang’s extensive background in business development and experience with biotech companies will likely accelerate the commercialization of their therapeutic pipeline, particularly for conditions such as Hemophilia and Duchenne muscular dystrophy. His expertise in deal-making and corporate strategy should provide HC Bioscience with the necessary leverage to solidify its position as a leader in genetic medicine.
